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Hematopoietic stem cellsHematopoietic stem cells (HSCs) hold great promise for the treatment of various diseases and blood disorders.
However, limited availability of these cells has hampered their applications in clinical and biological research.
Here we have identiﬁed a new source of autologous human HSCs in peritoneal dialysis (PD) efﬂuents from pa-
tients with end stage renal diseases (ESRDs). Cells isolated from PD efﬂuents contain a Lin−/CD34+/CD38−/
CD90+ sub-population and can repopulate NOD/SCID/gamma−/− mice in serial transplantation. Differing
from cord blood HSCs, PD-derived HSCs have high tendencies to repopulate peritoneal cavity and spleen with
myeloid cells and B lymphocytes. Repopulating HSCs also reside in peritoneal cavities in mice. The isolation of
HSCs from peritoneal cavities provides a novel and promising source of autologous and functional HSCs for
stem cell research and possible clinical use.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Hematopoietic stem cells (HSCs), deﬁned by their ability to self-
renew and differentiate into all blood cell types (Till and Mc, 1961;
Seita and Weissman, 2010), have been isolated from bone marrow
(Mathe et al., 1963), mobilized peripheral blood (Gianni et al., 1989),
and umbilical cord blood (Gluckmanet al., 1989). They hold great prom-
ise for the treatment of many diseases, including selected hematologic
malignancies, immunodeﬁciencies, hemoglobinopathies, bone marrow
failure syndromes, and congenital metabolic disorders (Bryder et al.,
2006). Previous studies indicate that, during development, hematopoi-
esis takes place in a variety of sites including yolk sac, aorta–gonad–
mesonephros, liver, spleen, and bone marrow. In adulthood, HSCs
mainly reside in the bone marrow, and also exist in extramedullary
organs including spleen and liver, especially during immune responses
following infection or during failed marrow hematopoiesis (Kim,
2010). Identiﬁcation of additional sources of HSCs will further our
understanding of the biology of HSCs and the interaction betweenneering, University of Texas at
tes.
hysiology and Developmental
nter, 5323 Harry Hines Blvd,
. Zhang), ltang@uta.edu
. This is an open access article understem cells and their microenvironment, and lead to the development
of new strategies of HSC-based therapies.
Our recent studies have revealed that subcutaneous implantation of
biomaterials promotes the recruitment of HSC to the implantation sites
(Nair et al., 2011). Although themechanism(s) of biomaterial-mediated
stem cell recruitment is unclear, it is likely that inﬂammatory products
released during foreign body reactions prompt the recruitment of
HSCs. To test whether such observations also hold true in humans,
we examined patients with end stage renal disease (ESRD) who
would undergo peritoneal dialysis (PD). Since PD patients have a cath-
eter implanted in the peritoneum prior to the treatment, we tested
whether dialysate efﬂuents from incident PD patients contained HSCs.
By analyzing cells isolated from PD efﬂuents following catheter implan-
tation, we identiﬁed a Lin−/CD34+/CD38−/CD90+ sub-population of
cells in PD efﬂuents. The hematopoietic multipotency of PD efﬂuent-
isolated HSCs was assessed using a transplantation assay. Concordant
with this result, we also identiﬁed functional HSCs from mouse perito-
neal cavity.
2. Materials and methods
2.1. Study population
Peritoneal dialysis (PD) ﬂuid samples were collected from 49 ERSD
patients visiting the University of Texas Southwestern Medical Center/
DaVita PD Clinic (Irving, TX) within a week after catheter implantationthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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catheter was ﬂushed with 1–2 l of dialysate solution (2.5% Dianeal PD
solution, Baxter, Deerﬁeld, IL), and the efﬂuent was collected for exper-
iment at the PD clinic after each cycle. The protocol of PD efﬂuent collec-
tionwas approved by the Institutional Review Board of theUniversity of
Texas Southwestern Medical Center at Dallas. Patients with peritonitis
were excluded from this study. Of all 49 patients, 12 had been on hemo-
dialysis (HD) for different periods of time prior to commencement of
PD, while 37 patients had no prior HD treatment. The demographic
information of the patients is listed in Table 1.2.2. Flow cytometry analyses of human PD efﬂuent samples
For ﬂow cytometry analysis, some of the recovered cells were
followed by lysis of RBC using RBC lysing buffer (Sigma Chemical Co.,
St Louis, MO) according to the manufacturer's instructions. For RBC
lysis, 5 ml of RBC Lysing Buffer was gently mixed and incubated
with the cell pellet collected from a patient efﬂuent at room tempera-
ture for 10 min. The mixture was diluted with 20 ml of medium
supplemented with FBS, and the cells were collected after centrifuga-
tion at 250–500g for 7 min. Cells were then washed in PBS, counted
and adjusted to 5 × 106/ml in ice cold PBS with 2% FBS, and stained
with monoclonal antibodies anti-human APC-CD90, FITC-CD34, PE-
CD38 (BD Bioscience, San Jose, CA), Biotin-Lineage cocktail (Miltenyi
Biotec Inc, Auburn, CA), and PE-Cy5.5-Strepavidin secondary antibody
(BD Bioscience, San Jose, CA) for HSCs staining. PE-CD3, PE-CD19, PE-
CD20, FITC-CD15, FITC-CD66b, PE-CD45, and PE-CD71 (BD Bioscience,
San Jose, CA) were also used for hematopoietic lineage staining.
FITC-CD34, PE-CD38 (BD Bioscience, San Jose, CA), Biotin-Lineage kit
(Miltenyi Biotec Inc, Auburn, CA), PE-Cy5.5-Strepavidin secondary anti-
body (BD Bioscience, San Jose, CA), APC-CD10, eFluo 450-CD45RA, and
APC-CD123 were used for progenitor cell staining. Stained cells were
analyzed on BD FACSCalibur or FACSAria (BD Bioscience, San Jose,
USA) for the presence of various hematopoietic populations.Table 1
Demographic characteristics of peritoneal dialysis patients.
Patient characteristics Number
Male 28
Females 21
Total 49
Median age (years) 52
Dialysis history
Prevalent patients 0
Race
African American 24
Caucasian 10
Hispanics 12
Asian/Paciﬁc Islander 3
Prior hemodialysis among incident patients
Prior hemodialysis 12
No prior hemodialysis 37
Causes of end stage kidney disease
Diabetes mellitus 22
Hypertension 12
Primary glomerulonephritis
IgA nephropathy (1)
Chronic glomerulonephritis (1)
2
Lupus nephritis 2
Autosomal dominant PKD 4
HIV nephropathy 2
Failed Kidney transplant 2
Chronic interstitial nephritis 0
Hepatitis C associated nephropathy 2
Unknown cause 12.3. In vivo repopulation in NSG mice
For the repopulation study, non-obese diabetic (NOD)-scid IL2rγnull
(NSG) mice were purchased and maintained at the University of Texas
Southwestern Medical Center animal facility. All animal experiments
were performedwith the approval of University of Texas Southwestern
Committee on Animal Care.
To study thehematopoieticmultipotencyof the cells derived fromPD
efﬂuents, freshly recovered peritoneal cells (1–10×107 cells per animal)
were injected intraperitoneally or intravenously via the retro-orbital
route into sub-lethally irradiated (2.5 Gy) 8- to 10-week-old NSG mice.
Eight weeks after transplantation, bone marrow cells from the recipient
mice were analyzed by ﬂow cytometry for the presence of human cells.
Monoclonal anti-human PE-CD45, PE-CD71, FITC-CD15, FITC-CD66b, PE-
CD19, PE-CD20, Biotin-CD3, APC-streptavidin secondary antibody, and
FITC-CD34 antibodies (BD Bioscience, San Jose, CA) were used for the
staining of human myeloid, lymphoid, and primitive cells (Zhang et al.,
2008). To compare different repopulation rates in organs, peritoneal la-
vage cells and spleen cells were also isolated from a few NSG recipient
mice for lineage staining.
To evaluate long term reconstituting potential of PD derived HSCs,
bone marrow aspirates from one hind leg of a primary recipient, or
peritoneal lavage cells, or spleen cells from a primary recipient were
transplanted into a secondary recipient (Zhang et al., 2008; Hogan
et al., 2002). For limiting-dilution analysis, mice were considered
positive for human HSC engraftment when at least 1% (for primary
transplantation) or 0.1% (for secondary transplantation) CD45/71
human cells were detected among the mouse bone marrow cells
(Zhang et al., 2008).
2.4. Hematopoietic colony assays
Freshly isolated peritoneal cells followed by RBC lysis were washed
in PBS and diluted to 1 × 106/ml in Iscove's modiﬁed Dulbecco's
medium (IMDM) with 2% FBS, and then seeded into methylcellulose
medium H4436 (StemCell Technologies) for CFU-GEMM, CFU-GM, and
BFU-E colony formation, according to the manufacturer's protocols
(Zheng et al., 2011a; Zhang et al., 2006).
2.5. EGFP transgenic mice peritoneal cell transplantation and repopulation
study
For the mice peritoneal cell transplantation study, EGFP negative
C57BL/6 mice (6–8 weeks old) were used and maintained at the
University of at Arlington animal facility. The animal use protocol was
approved by the Institutional Animal Care and Use Committee of
the University of Texas at Arlington. EGFP negative C57BL/6 mice
(6–8 weeks old) were irradiated (whole body X-ray irradiation) at
1000 cGy and then transplanted with sex matched peritoneal cells iso-
lated from EGFP transgenic mice through retro-orbital injection. Eight
weeks after transplantation, peripheral blood and peritoneal cells of
recipient mice were isolated for ﬂow cytometry analysis for GFP+
hematopoietic lineage markers Thy1.2, B220, Mac-1, and Ter119 essen-
tially as we described (Kang et al., 2015). Eighteen weeks after trans-
plantation, peripheral blood, peritoneal cells, bone marrow cells, and
spleen cells of recipient mice were collected for GFP+ lineage marker
analysis again to check long-term peritoneal HSCs.
2.6. Statistical analysis
Data are expressed as Mean ± SEM. IBM SPSS Statistics 19 software
was used for analysis. Signiﬁcant levels were calculated using student's
t-test. One-way ANOVA and post-hoc Scheffe's test were used for
comparisons between multiple groups. Differences were considered
signiﬁcant when p b 0.05.
Fig. 1. Characterization of hematopoietic cells isolated from PD efﬂuents. Representative ﬂow cytometry plots reveal the presence of (A) Lin−/CD34+/CD38−/CD90+cells, N = 140,
(B) CMP (Lin−/CD34+/CD38+/IL3Ralow/CD45RA−), MEP (Lin−/CD34+/CD38+/IL3Ra−/CD45RA−), GMP (Lin−/CD34+/CD38+/IL3Ralow/CD45RA+), and CLP (Lin−/CD34+/CD38+/
CD10+) cells in a PD sample, N = 5. (C) The frequencies of various hematopoietic populations and CD3+T lymphocytes, CD19+/CD20+ B lymphocytes, CD15+/CD66b+ myeloid cells,
and CD71+ erythroid cells in PD efﬂuent cells were also determined. N = 5. (D–F) The numbers and frequencies of Lin−/CD34+/CD38−/CD90+ cells in PD efﬂuents recovered from 49
patients at different times (0–100 days, N = 140 for D/E and N = 120 for F) following peritoneal catheter implantation were quantiﬁed using ﬂow cytometry. Vertical lines denote
±1 SEM.
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By analyzing surface markers of cells isolated from PD efﬂuents, we
identiﬁed a Lin−/CD34+/CD38−/CD90+ (~0.14±0.03%) subpopulation
(Fig. 1A), which are known to enrich for human HSCs. PD cells also
contain phenotypic hematopoietic progenitors including commonmye-
loid progenitors (CMP), megakaryocyte–erythroid progenitors (MEP),
granulocyte/monocyte progenitors (GMP), and common lymphoid pro-
genitors (CLP) (Fig. 1B). The overall peritoneal cells further include
CD3+T-lymphocytes, CD19+/CD20+B-lymphocytes, CD15+/CD66b+
myeloid cells, and CD71+ erythroid cells (Fig. 1C). After analyzing all
samples, we found that the phenotypic HSCs were consistently present
in the PD efﬂuents isolated from different patients at different times
(Fig. 1D–F). Statistically, analyses revealed that a patient's gender, age,prior hemodialysis (HD) treatment and duration following catheter
transplantation had no inﬂuence on the numbers of Lin−/CD34+/
CD38−/CD90+ cells found in the PD efﬂuents. The existence of hemato-
poietic progenitors was also conﬁrmed by colony formation assays
(Supplemental Fig. 1) (Zheng et al., 2011b, 2012). Additional analyses
revealed that, on average, about 5.6 × 104 Lin−/CD34+/CD38−/CD90+
cells can be recovered from one PD efﬂuent sample. There were on
average 2.8 × 105 phenotypic HSCs acquired from5 efﬂuents of each pa-
tient during the PD training period. The frequency and number of HSCs
acquired from PD efﬂuents and patients varies greatly (Supplemental
Fig. 2). The reason(s) for such variations remain undetermined.
However, statistical analyses have excluded the inﬂuence of prior he-
modialysis, gender, and ages on PD-derived HSC numbers. In addition,
the numbers of phenotypic HSCs recovered from PD efﬂuents did not
Fig. 2. Human PD-derived HSCs are capable of repopulating myeloid and lymphoid lineages in NSG mice. (A) Representative ﬂow cytometry plots show multi-lineage repopulation of
donor human cells including monoclonal anti-human CD45+/CD71+ human hematopoietic cells (abbreviated as Total), CD15+/CD66b+ myeloid cells (Mye), CD19+/CD20+/CD34− B
lymphocytes (B-Lym), and CD34+ primitive cells (Pri). (B) The percentage of different types of human hematopoietic cells in the recipient mice bone marrow were quantiﬁed 8 weeks
after human peritoneal cell implantation. N = 9. (C) Bone marrow cells isolated from bone marrow of primary transplanted mice were used for secondary transplantation. Different
types of human hematopoietic cells in mouse bone marrow following secondary transplantation were quantiﬁed. N = 5. Vertical lines denote ±1 SEM.
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suggest that HSCs are either resident cells or continuously replenished
in the peritoneal cavity.
The functionality of these phenotypic HSCs isolated from PD
efﬂuents was evaluated by transplantation into sub-lethally irradiated
NOD/SCID/gamma−/− (NSG) mice (Zheng et al., 2012). Fig. 2A
shows multi-lineage engraftment of total hematopoietic (CD45/71+),
myeloid (CD15/66b+), B-lymphoid (CD34−CD19/20+), and primitive
(CD34+) human cells. Collectively, for 107 donor cells, there were
2.87 ± 1.66% total human hematopoietic cells, 0.80 ± 0.70% myeloid
cells, 0.19 ± 0.09% lymphoid cells, and 0.92 ± 0.53% primitive cells in
recipient bone marrow (Fig. 2B), attesting the existence of functional
HSCs in the donor population. To assess self-renewal and long-term
functionality of PD-derived HSCs, we collected bone marrow cells
from the primary mice and then transplanted them into sub-lethally
irradiated secondary recipients. The donor-derived cells showed
comparable positive engraftment of B-lymphoid cells (0.97 ± 0.54%) in
bone marrow as in the primary recipients, and lower engraftment of
myeloid cells (0.070 ± 0.031%) and primitive cells (0.019 ± 0.007%)
(Fig. 2C). Together, our results imply that PD-derived HSCs contain
repopulating HSCs. Finally, the transplantation routes (intraperitoneal
and intravenous injection) have no effect on the ﬁnal outcome of
chimerisms.
To investigate whether PD-derived HSCs behave differently from
HSCs from other sources, we compared the engraftment of 107 human
PD cells and 105 human cord blood (CB) CD34+ cells in different
tissues/organs of the recipient mice via intravenous injection. At 2
months post-transplantation, the indicated number of CB mononuclear
cells had a greater engraftment in the recipient bone marrow, whereasFig. 3. Comparative study of the repopulation and differentiation capability of PD-derived HSC
isolated from different sources, PD-derived HSCs (labeled as “Human PD donor”) and cord blo
mice. At 2months post-transplantation, bonemarrow cells from the transplanted animals were
centages of different hematopoietic lineage cells in different organswere compared between dif
are found in higher percentages than those in bone marrow. N = 8. (C–D) Functional charact
peritoneal cells were isolated from EGFP transgenic C57BL/6 mice and mixed with 105 GFP-C
through retro-orbital injection. Cells isolated from themice peripheral blood (labeled as “PB”) a
of hematopoietic cells, including B220+ B lymphocytes, Mac-1+myeloid cells, Thy1.2+ T lymph
N = 6. (E) Representative ﬂow cytometry plots showing the GFP+ compartment contained mthe PD cells repopulated better in the peritoneal cavity and spleen, and
produced higher percentages of myeloid cells and B-lymphocytes than
CB counterparts (Fig. 3A). We suspect that, after residing in the perito-
neal cavities, PD-derived HSCs are “primed” to initiate adaptive and
innate immune responses against potential invasion of pathogens
through intestinalmucosa. It is also possible that PDHSCs have a certain
disadvantage while homing to recipient bone marrow. While we did
carry out intrafemoral transplantation, this type of injection can only
administer a volume less than 20 μl. This small injection volume is insuf-
ﬁcient for PD cells to produce detectable reconstitution. To explain the
“primed”properties,we believe that donor PDHSCs have distinct intrin-
sic potential asc compared to bonemarrow or cord blood HSCs.We also
suspect that the recipient peritoneal and extramedullary sites provide
unique microenvironment for PD HSCs to home and differentiate.
To investigate whether PD-derived HSCs exist in other mammals,
we analyzed the resident cells in the peritoneal cavity of C57BL/6
mice without any prior treatment. We found that there was a higher
ratio (0.51 ± 0.04%) of Lin−/Sca1+/c-kit+ population in the mouse
peritoneal cavity than in bonemarrow (0.05 ± 0.01%) (Fig. 3B). Similar
observations were also noted in Balb/C mice. These results support that
PD derived HSCs may reside in the rodent peritoneal cavity. We believe
that amuch higher frequency of peritoneal cavity HSCs than BMHSCs is
contributed by the fact that the total cell number in peritoneal cavity is
low (~106 cells per mouse). Because infection may frequently occur in
the peritoneal cavity, a high frequency of HSCs in the peritoneal cavity
may help to ﬁght infection by timely differentiation into different
types of hematopoietic and immune cells.
To characterize their function and repopulation capability, HSCs iso-
lated from EGFP+ C57BL/6 mice' peritoneal cavities were transplanteds and cord blood HSCs, and mouse peritonea HSCs. To investigate the responses of HSCs
od HSCs (labeled as “Human CB donor”) were transplanted in sub-lethally irradiated NSG
recovered and then analyzed for the presence of human hematopoietic cells. (A) The per-
ferent sources of cells. N=4. (B) Resident Lin−/Sca-1+/c-kit+HSCs in themouse peritonea
erization of mouse peritoneal HSCs was carried out using reconstitution analysis. 5 × 106
57BL/6 bone marrow cells, and was then transplanted into each irradiated C57BL/6 mice
nd peritoneal dialysis (labeled as “PD”) were analyzed for the presence of different lineages
ocytes, and Ter119+ erythroid cells, at 8weeks (C) and (D) 18weeks post-transplantation.
ulti-lineage repopulating cells. Vertical lines denote ±1 SEM.
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injection. Eight weeks later, in GFP+ repopulated cells, we found signif-
icantly higher percentages of B-lymphocytes (55.73±1.97% vs. 31.82±
7.54%) and macrophages (61.23 ± 4.30% vs. 18.44 ± 12.11%) in the
peritonea than in the peripheral blood (Fig. 3C). There were higher per-
centages (43.54 ± 6.04% vs. 9.09 ± 1.20%) of T-lymphocytes in the pe-
ripheral blood than in the peritonea. Further analyses were carried out
on the same animals after implantation for 18 weeks. The results re-
vealed similar trends of cell distribution in which substantially higher
percentages of B-lymphocytes (43.06 ± 3.47% vs. 29.33 ± 0.71%) and
Mac-1+ myeloid cells (42.43 ± 3.83% vs. 14.25 ± 3.46%) were found
in the peritonea than in the peripheral blood (Fig. 3D). This bias of
peritoneal cavity HSCs to differentiate into B cells or macrophages
may be beneﬁcial to immune actions in response to infections. The
percentages of erythroid cells were slightly higher in peripheral blood
than in the peritonea. The mouse peritoneal HSCs possess properties
different from peripheral HSCs or inﬂammatory cells. We used 105 of
donor peripheral blood mononuclear cells from CD45.1 C57BL/6 mice
and performed a similar competitive reconstitution analysis, and did
not observe donor engraftment in CD45.2 C57BL/6 recipient mice.
HSCs from other periphery inﬂammatory sites such as tumor stroma
also have much lower repopulation activity (Huynh et al., 2011), com-
pared to peritoneal HSCs. These results support that mouse peritonea
contain repopulating HSCs, and peritoneal HSCs have great potential to
differentiate into B-lymphocytes and macrophages in the peritonea. It is
plausible that due to frequent infections in the peritoneal cavity, a high
frequency of HSCs on site will help timely differentiation into different
types of hematopoietic and immune cells to combat infections. In accor-
dance with the fact that there exist myeloid- and lymphoid-biased sub-
populations of HSCs (Muller-Sieburg et al., 2002; Oguro et al., 2013;
Beerman et al., 2010; Dykstra et al., 2007; Kent et al., 2009; Challen
et al., 2010; Morita et al., 2010; Ema et al., 2005; Benveniste et al.,
2010), we suspect that the donor peritoneal HSCs have distinct intrinsic
potentials than bone marrow or cord blood HSCs. We also suspect that
the recipient peritoneal and extramedullary sites provide a uniquemicro-
environment for peritoneal HSCs to home and differentiate. Future com-
parison of properties of peritoneal and bone marrow HSCs in gene
expression, cell fates, immune privilege, and metabolic feature (Zheng
et al., 2011b, 2011c; Zhang, 2012; Zhang and Sadek, 2014; Simsek et al.,
2010) are warranted. We believe that peritoneal HSCs may serve as a
promising source of autologous HSCs, and efforts to utilize these cells,
as in stem cell banking, may prove beneﬁcial to stem cell research and
clinical treatment.
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